Insulet stock holds firm after August 5 earnings beat
Published on 08/20/2026 at 21:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Insulet Corporation (US45784P1012) held attention on August 20, 2026 after the August 5 quarter showed $801.7 million in revenue and $1.66 in earnings per share, both above consensus in the latest reported period.
The shares opened at $151.51, with a market capitalization of $10.51 billion, a 52-week range of $126.40 to $354.88, and a 50-day moving average of $154.75.
Earnings still set the tone
The quarter ended June 30, 2026 came with a revenue comparison that mattered: $801.7 million versus $787.39 million expected, while EPS of $1.66 beat the $1.47 consensus by $0.19. That kind of gap can keep focus on execution even when the broader tape is mixed.
Insulet also set FY 2026 guidance at 6.460 EPS, while analysts in the latest estimate table were looking for $6.48 for the current year and $8.05 for 2027. The market is still weighing whether the latest quarter supports that range or leaves little room for disappointment.
What the numbers say
Market data put the stock at $151.51 on August 20, 2026, still below the 50-day average of $154.75 and far under the 200-day average of $185.83. That spread suggests the share price is still digesting the earlier reset tied to growth expectations.
On the balance-sheet side, the same snapshot showed debt-to-equity of 0.65, a current ratio of 2.48, and a quick ratio of 1.83. Return on equity stood at 29.29%, while net margin came in at 12.29% in the latest quarter.
Pod and dosing
Omnipod remains the product most closely tied to Insulet's growth story. It is the platform that links the company's sales, margin profile, and guidance trajectory across diabetes management.
The stock traded at $151.51 as of August 20, 2026, with a one-year low of $126.40 and a one-year high of $354.88. For investors, the key question is whether the latest quarter and FY 2026 outlook can narrow the gap to the longer-term average.
Company details
Company: Insulet Corporation
ISIN: US45784P1012
Ticker: PODD
Exchange: NASDAQ
Price (as of August 20, 2026): $151.51 USD
Market cap: $10.51 billion
Sector / Industry: Health Care / Medical Instruments & Supplies
